-+ 0.00%
-+ 0.00%
-+ 0.00%

Eloxx's Exaluren Increases Kidney Collagen IV in Phase 2a Alport Syndrome Study

PUBT·11/18/2026 21:07:07
Listen to the news
Eloxx's Exaluren Increases Kidney Collagen IV in Phase 2a Alport Syndrome Study
  • Eloxx Pharmaceuticals published Phase 2a results for exaluren in nonsense mutation Alport syndrome in the Journal of Clinical Investigation.
  • All three participants, aged 12 to 18, showed increased kidney collagen production with partially improved kidney cell structure following eight weeks of treatment.
  • Proteinuria changes were inconsistent; blood in the urine persisted in all participants.
  • Exaluren was well tolerated, with no serious adverse events, kidney toxicity or hearing toxicity.
  • The findings support the ongoing Phase 2b EXACT study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eloxx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611181605PR_NEWS_USPR_____NE01847) on November 18, 2026, and is solely responsible for the information contained therein.